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Background: In patients treated with IVF, the incidence of poor ovarian response (POR) after ovarian stimulation
varies from 9 to 25 %. However, at present, there are no clear guidelines for treating these poor responders. This
study was designed to compare two different ovarian stimulation protocols and addresses future perspectives in
the management of these unfortunate patients.
Method: Four hundred and forty poor responders were studied during their second IVF cycle. They had all failed to
become pregnant during their first IVF cycle where the long GnRH-agonist stimulation protocol (P1) was used.
Patients were prospectively randomly assigned to 2 protocol groups (P2 or P3, 220 patients in each arm) at the start
of ovarian stimulation according to the order of entry into the study including one patient per each stimulation
protocols: The P2 group was treated with a contraceptive pill + flare-up GnRH-agonist protocol and the P3 group
with the GnRH-antagonist protocol. The ovarian stimulation characteristics as well as the clinical and ongoing
pregnancy rates were compared.
Result(s): Although the numbers of embryos obtained and transferred were significantly higher with the P2 protocol,
the implantation and ongoing pregnancy rates per transfer were the same in the two studied groups (8.9 % versus
14.6 % and 8.4 % versus 14.2 % for the P2 and P3 protocols, respectively). Good prognostic factors for ongoing
pregnancy with both protocols were: a maternal age <36, no tobacco consumption, a total dose of gonadotropins
injection <5000 IU and an endometrial thickness >10 mm.
Conclusion(s): In poorly responding patients treated with IVF, the implantation and ongoing pregnancy rates per
transfer were not significantly different between the two protocols studied: contraceptive pill + flare-up GnRH-agonist
protocol and the GnRH-antagonist protocol. It is suggested that current strategies for the management of poor
responders be reconsidered in the light of the potential contribution of age and the effect of life style changes
on fertility potential. A customised policy of ovarian stimulation in these patients including mild stimulation
protocols, sequential IVF cycles, oocytes-embryos freeze all protocols and blastocyst transfers after screening may
improve the clinical outcome.
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In routine IVF programs, the incidence of poor ovarian
response (POR) after ovarian stimulation varies from 9
to 25 % of patients [1]. This poor response can be re-
lated to different causes such as age, endometriosis,
ovarian surgery, genetics factors or may be iatrogenic.
Although there is a lack of uniform definitions of poor
response [2], the most common criteria used for diagno-
sis of poor responders is a low number of retrieved oo-
cytes despite adequate ovarian stimulation [3].
Recently, an ESHRE consensus conference [4] pub-
lished the “Bologna criteria” and defined the poor ovar-
ian response by the presence of two of the following
three features: (i) advanced maternal age (≥40 years) or
any other risk factor for POR; (ii) a previous character-
ized POR cycle (≤3 oocytes with a conventional stimula-
tion protocol); (iii) an abnormal ovarian reserve test
(antral follicle count <5-7 follicles or AMH <0.5-1.1 ng/ml).
Several controlled ovarian hyper stimulation (COH)
strategies have been described for treating poor re-
sponders, but at present, there are no clear guidelines
for treating those patients. In practice many clinicians
are increasing the daily gonadotropins dose (up to 450–
600 IU/d), despite the lack of supporting evidence [5, 6].
The use of gonadotropin-releasing hormone agonist
(Gn-RH agonist) long protocol in IVF leads to ovarian
desensitization, resulting in a reduction in the number
of mature follicles and the need to increase the dose of
gonadotropins in poor responders [7, 8]. Other investiga-
tors have reported the advantages of the initial endogen-
ous gonadotropin “flare” induced by Gn-RH agonist,
enhancing the effect of exogenous gonadotropins [9, 10].
Given that significant increases in serum estradiol, an-
drogen and progesterone levels have been noted with
this protocol, Lindheim et al. [11] suggested that pa-
tients in whom Gn-RH agonist long protocol had
failed might benefit from a combination of a pre-cycle
oral contraceptive pill treatment and a micro dose Gn-
RH agonist flare-up protocol. On the other hand, the
introduction of GnRH antagonists (GnRH antagonist)
have presented a hope for the poor responders in view
of its immediate suppression of LH, the absence of
flare-up effect, the reduction of the duration of stimu-
lation and the dose of gonadotropins used. In poor
responders, Fasoulitis et al. [12] using a GnRH antag-
onist protocol in poor responders reported a non-
significant trend towards higher implantation and
clinical pregnancies rates. However, other workers re-
ported higher cancellation rates [13] or a reduced
number of retrieved oocytes without a difference in
the clinical pregnancy rate [14].
The aim of this prospective study was to compare two
different protocols in poor responders who had one IVF
failure when using a long GnRH agonist protocol, and toevaluate the perspectives and challenges facing poorly
responding patients requiring IVF therapy.
Materials and methods
Poor responders included in this study were defined as
those patients from whom less than 4 mature oocytes
were retrieved in the first stimulated IVF cycle using the
Gn-RH agonist long protocol (P1 protocol). During this
P1 protocol all patients were treated with triptorelin
(0.1 mg/day SC, Decapeptyl®, Ipsen, Paris, France) from
day 20 of the previous cycle, for 14 days. After achieving
desensitization, the dose of triptorelin was diminished to
(0.05 mg/day SC) and, at the same time, a fixed-dose of
gonadotropin FSH or hMG (375 IU/day, SC) was started
and injected daily until the day of hCG administration.
Study design
After failure of the first IVF cycle using the long GnRH
agonist protocol, 440 women were prospectively ran-
domized, after an interval of less than 4 months, to a
prospective study comparing two other protocols (Fig. 1).
The study design included two parallel groups with the
same size using block randomization. The 440 patients
were prospectively randomly assigned to 2 groups (220
patients per each) at the start of ovarian stimulation.
The randomization of the two protocols (P2 or P3) was
made according to the order of entry into the study in-
cluding one patient per each stimulation protocols:
Protocol 2, then 3, and so on. In this study, there was no
control group. Protocol 1 is the basis of our definition of
poor responders and the comparison is made between
protocol 2 and protocol 3.
Ethical considerations
The authors assert that all procedure contributing to this
work comply with the ethical standards of the relevant
(our) national and institutional committees on human
experimentation and with the Helsinki declaration of
1975, as revised in 2008. All patients who participated in
this study signed an informed consent after being in-
formed about the terms and issues of the study.
Stimulation protocols
Two stimulation protocols were compared:
1. A flare-up GnRHa protocol (P2 protocol): this
group consisted of 220 women received a low
dose oral contraceptive pill (Desolett®, MSD,
Courbevoie, France) started on cycle day 1 of the
previous cycle for 21 days. Three days after the
end of the pill, triptorelin (0.025 mg/day) and
a fixed-dose of gonadotropin FSH or hMG
(375 IU/l) were administered until the day of hCG
injection.
Fig. 1 Chronology of the study
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second group consisted of 220 women, in whom, on
day 2 of a spontaneous cycle, gonadotropin stimulation
was initiated at a fixed-dose of 375 IU/day. When the
leading follicle reached 14 mm in mean diameter and/
or plasma E2 exceeded 400 pg/ml and/or LH serum
levels were >10 IU/l, an injection of 0.25 mg of
cetrorelix GnRH antagonist (Cetrotide®, Merck
Serono, Lyon, France) was administered SC daily until
the day of hCG administration.
For controlled ovarian hyperstimulation (COH), we
used urinary FSH (Fostimon®, Genevrier, Sophia-Antipolis,
France), recombinant FSH (Gonal-F®, Merck Serono,
Lyon, France; Puregon®, MSD, Courbevoie, France) or
human menopausal gonadotropin hMG (Menopur®,
Ferring SAS, St Prex, Switzerland), and as in the P1
protocol the FSH or hMG fixed dose was not adjusted
according to the ovarian response. When at least three
follicles reached a diameter of >17 mm, a dose of 250 μg
of recombinant human chorionic gonadotropin (Ovitrelle®,
Merck Serono, Lyon, France) was administered and
trans-vaginal oocyte retrieval was performed 35–36 hours
after hCG administration. Plasma E2 and plasma proges-
terone levels were measured on the day of hCG adminis-
tration. Cycle cancellation was recommended when less
than three mature follicles were observed. Intracytoplas-
mic sperm injection (ICSI) was performed only in cases
with severe male factor or previous fertilization failure.
For this procedure, the cumulus and corona radiata were
exposed to 0.5 % hyaluronidase (Sigma Company, NY,
USA) for 30s and removed mechanically under a
dissecting microscope. After 18 h of incubation at 37 °C in
a humidified atmosphere with 5 % CO2, oocytes were
examined for the presence of two pronuclei, as a sign of
fertilization. The embryos obtained were characterizedinto four grades depending on their morphological ap-
pearance (blastomere number and size, cytoplasmic
fragmentation) as described by Terriou et al. [15].
Grade I/II embryos (high and good quality) were those
with equal blastomeres and absence of or <20 % cyto-
plasmic fragmentation. A maximum of three embryos
were transferred on day 2 or 3, using Frydman catheter
(CCD, Paris, France). Other good-quality embryos were
cryopreserved.
The luteal phase was supported by vaginal administra-
tion of 200 mg of micronized progesterone twice a day
(Utrogestan®; Besins International, Paris, France), start-
ing on the day of oocyte pick-up and continued for
20 days. Clinical pregnancy was diagnosed when serum
β-hCG concentration was >1000 IU/l. Ongoing preg-
nancy was defined as the presence of an intrauterine
gestational sac with cardiac activity 12 weeks after oo-
cyte retrieval.
The demographic and medical data were recorded in-
cluding the woman’s and man’s age, the type and dur-
ation of infertility, the woman’s body mass index (BMI)
and any tobacco use. Day-3 follicle-stimulating hormone
(FSH), luteinizing hormone (LH), 17β-estradiol (E2), in-
hibin B and anti-Müllerian hormone (AMH) serum
levels were also measured.
Statistical methods
Data were analyzed using Stat View for Windows, ver-
sion 5.0.1 software (SAS Institute Inc., Cary, NC) and
presented as mean +/− standard deviation (SD) or a
standard number representing the total. The Student’s t-
test or Mann–Whitney U test were used to compare
continuous variables (mean ± SD), while the chi-square
test or Fisher’s exact test were used to calculate the clin-
ical and ongoing pregnancy rates. A P value < 0.05 was
considered to be statistically significant with bilateral
Table 2 Patient characteristics in the P2 and P3 protocols
P2 P3 P value*
Number of patients 220 220
Number of cycles 220 220
Age of woman (y) 38.0 ± 3.7 37.8 ± 3.1
Age of man (y) 38.4 ± 5.6 38.0 ± 6.2
BMI of woman (kg/m2) 24.6 ± 2.7 24.7 ± 2.8
Woman with tobacco use (%) 38.1 38.6
Day 3 FSH (IU/l) 9.7 ± 3.0 9.6 ± 3.1
Day 3 LH (IU/l) 3.9 ± 2.5 4.2 ± 2.0
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evaluated to calculate the study power by post-hoc test
using G*Power software (version 3.0.1). The power cal-
culation showed that two samples of 220 patients re-
sulted in a power of 80 % if the difference in percentage
was 15 %. Multivariate logistic regression analysis was
used to test the correlation between clinical variables on
one hand and the occurrence of pregnancy on the other.
Odds ratios (ORs) and 95 % confidence intervals (95 %
CIs) were calculated separately for each factor. Confi-
dence intervals exclusive of unity were considered to be
significant.Mean day 3 estradiol (± SD) (pg/ml) 70.5 (8.3) 69.3 (6.4)
Mean day 3 inhibin B (± SD) (IU/l) 35.5 (5.2) 40.0 (5.1)
Mean day 3 AMH (± SD) (ng/ml) 1.2 (0.4) 1.3 (0.7)
% of patients with a total day 3–5
antral follicles < 6
27.2 25.9
Duration of infertility (± SD) in y 4.6 (2.1) 4.7 (2.0)




Endometriosis stage I or II 12.2 10.0
Mixed 12.2 14.0
Unexplained 13.4 15.6
P value*: All are not significantResults
Four hundred forty-two women, identified as “poor re-
sponders” after P1 protocol, underwent a second IVF
treatment cycle between 2004 and 2011 at Amiens Uni-
versity hospital, and were randomized between P2 and
P3 protocols. The results of the P1 protocol (n: 462) are
reported in Table 1. Twenty two women had an ongoing
pregnancy and were excluded from the prospective
study. After randomization, the characteristics of the P2
and P3 protocol groups are shown in Table 2. There
were no significant differences between the P2 and P3
groups in age, BMI, tobacco use, criteria of ovarian re-
serve, duration of infertility, type or indication of infertil-
ity. The stimulation cycle characteristics of the P2 and
P3 groups are displayed in Table 3. Sixty-five percent of
the cycles were ICSI procedures, with similar percentage
in the two groups. Significant differences between P2Table 1 Ovarian stimulation results in the P1 protocol
Number of cycles 462
Total FSH/hMG dose (IU) 4754 ± 684
Duration of stimulation (days) 12.6 ± 2.1
Mean estradiol levels on hCG day (pg/ml) 914 ± 307
Endometrial thickness (mm) 8.5 ± 1.6
Number of cancelled cycles (%) 75 (16.6)
Number of oocyte pick-ups 387
Number of oocytes retrieved (per pick-up) 1716 (4.5 ± 1.9)
Number of M2 oocytes retrieved 1437 (3.8 ± 2.8)
Number of oocytes fertilized 982
Number of embryos obtained 618 (1.6 ± 0.4)
Number of embryos transfer (per transfer) 329
Embryos per transfer 1.5 ± 0.3
Clinical pregnancy rate per transfer (%) 9.1
Ongoing pregnancy rate per transfer (%) 6.6
Implantation rate per embryo transferred (%) 6.0
Number of cycles with cryopreservation (%) 4.5
Number of cryopreserved embryos 35and P3 groups were noted in terms of the mean estradiol
levels on the hCG administration day (1215 ± 350 vs.
712 ± 251 pg/ml; p < 0.001), embryos obtained (2.3 ± 0.5
vs. 2.1 ± 0.3; p < 0.001) and transferred (2.0 ± 0.2 vs.
1.9 ± 0.4; p < 0.01), but not in the ongoing pregnancy
rate and the implantation rate per embryo transferred
(p > 0.05). No twin or triplet gestations were seen in
this study. The overall cancellation rate was the same
for the two groups (P2: 19 % vs. P3: 23.1 %), despite a
trend toward a higher cycle cancellation rate due to
poor ovarian response in the P3 group (10.9 vs. 7.2 %;
p > 0.05). The percentage of grade I/II embryo was not
significantly different between the two groups (35.9 vs.
36.8 %). The fertilization and cleavage rates were the
same in both groups. The clinical, ongoing and im-
plantation rates were similar in P2 and P3 groups
(17.9 % versus 14.6 %, 8.9 % versus 15.9 % and 14.2 %
versus 8.4 %, respectively).
There was no significant difference between stimula-
tion with FSH or hMG in the P2 and P3 protocols re-
garding the studied parameters. Prognostic factors of
pregnancy during P2 and P3 protocols, obtained by a
multivariate analysis, are summarized in Table 4. In con-
trast, no significant difference in clinical pregnancy rates
was found in terms of man age, infertility duration, BMI,
day 3 ovarian reserve evaluation (FSH, LH, estradiol,
Table 3 Ovarian stimulation results in the P2 and P3 COH
protocols
P2 P3
Number of cycles 220 220
Total FSH/hMG dose (IU) 4664 ± 605 4680 ± 641
Duration of stimulation (days) 11.8 ± 2.3 11.6 ± 2.7
Estradiol levels on hCG day (pg/ml) 1215 ± 350a 712 ± 251b
Progesterone levels on hCG
day (ng/ml)
0.8 ± 0.2 0.7 ± 0.3
Endometrial thickness (mm) 8.7 ± 1.3 8.4 ± 1.2
No of oocyte pick-ups 204 196
No of oocytes retrieved (per pick-up) 1224 (6.0 ± 4.1) 1218 (6.2 ± 4.9)
No of M2 oocytes retrieved 894 (4.3 ± 3.7) 913 (4.6 ± 4.1)
No of oocytes fertilized 721 694
No of embryos obtained 487 (2.3 ± 0.5)a 426 (2.1 ± 0.3)b
Grade I/II embryos (%) 35.9 36.8
No of overall cancelled cycles (%) 42 (19.0) 51 (23.1)
No of embryos transfer 178 169
Embryos per transfer 2.1 ± 0.2c 1.9 ± 0.4d
Clinical pregnancy rate per
transfer (%)
17.9 15.9
Ongoing pregnancy rate per
transfer (%)
14.6 14.2
Implantation rate per embryo
transferred (%)
8.9 8.4
No of cycles with cryopreservation (%) 15.7 9.4
No of cryopreserved embryos 69 43
a-b: significant difference at p < 0.001
c-d: p < 0.01
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estradiol level on hCG day.
Discussion
Definition of poor responders is still debated and many
clinicians are using the Bologna criteria with or without
adaptation according to personal experience [4, 16, 17].
In this study, we defined poor response as the retrieval
of less than 4 mature oocytes with the long GnRH-
agonist protocol, with a decrease of GnRH-agonist to
0.05 mg/day) after desensitization, as described by Feldberg
et al. [7] and Olivennes et al. [8]. Using this definition, our
current randomized study showed that, in those patients,Table 4 Prognostic factors in the P2 and P3 protocols correlated
with occurrence of clinical pregnancy (in a multivariate analysis)
Factors OR 95 % CIs p
Female age < 36 2.39 1.45-3.34 <0.01
No woman tobacco use 3.05 1.62-4.48 < 0.02
Total dose of FSH/hMG < 5000 IU 1.77 1.11-2.93 < 0.05
Endometrial thickness > 10 mm 2.48 1.57-3.39 < 0.01the implantation and ongoing pregnancy rates per transfer
were not significantly different between the contraceptive
pill + flare-up GnRH-agonist P2 protocol and GnRH-
antagonist P3 protocol.
The idea of using extremely low doses of GnRH-
agonist in a flare regimen after oral contraceptive pre-
treatment (similar to our P2 protocol) has been reported
by Surrey et al. [18] in 44 patients who had a poor re-
sponse in a previous cycle stimulated with a long
GnRH-agonist protocol (≤3 oocytes). Patients were di-
vided into two groups, based on age (group 1: 15
women ≤ 39 years; group 2: 19 women ≥ 40 years). The
cycle cancellation rate was dramatically reduced and the
mean E2 level on hCG day was significantly increased
with the pill + microdose flare-up GnRH-agonist proto-
col. The ongoing pregnancy rates per embryo transfer
were 33 % in group 1 and 18.2 % in group 2. In contrast,
three retrospective studies (Yakin et al. [19], Weissman
et al. [20] and Detti et al. [21]) did not found any signifi-
cant difference in clinical outcomes between the short
flare-up microdose protocol compared to the long
protocol with decreasing doses of the GnRH-agonist de-
scribed by Faber et al. [22].
Several investigators have evaluated the role of GnRH-
antagonist protocols in the treatment of poor responders.
D’Amato et al. [23] reported in a study comparing the use
of antagonists and the agonists in poor-responder women
aged over 35. They found a lower cancellation cycle rate
(4.7 % vs. 34.0 %, p < 0.0001), a higher number of oocytes
(5.5 vs. 3.3, p < 0.0001) and embryo implantation rate
(13.5 % vs. 7.6 %, p: non-significant) in the antagonist
group. In another retrospective study, Berin et al. [24]
found no significant difference in any IVF parameters and
outcomes between the GnRH-antagonist (n: 68) and
GnRH-agonist flare-up (n: 45) protocols. The only pro-
spective, randomized trial investigating GnRH antagonist
and microdose GnRH-agonist flare-up protocols in poor
responders [14] reported no significant difference in out-
comes, despite a trend towards higher implantation rates
(15.0 vs 11.3 %) and ongoing pregnancy rates (21.0 vs
16.6 %) with the microdose GnRH-agonist flare-up proto-
col. However, despite an improvement in blastulation rate
in the GnRH-antagonist protocol compared to the long
GnRH-agonist protocol [25], there was no significant dif-
ference in the number and maturation rate of retrieved
oocytes in both protocols, but only a slightly lower (but
non-significant) implantation rate per transferred embryo
with the GnRH-antagonist protocol [26, 27]. Moreover, the
use of low-dose oral contraceptive from day 1 to 21 of the
previous cycle did not result in any improvement in the
final outcome, as shown in the studies of Malmusi et al.
and Papras et al. [28, 29].
One of the major challenges in ovarian stimulation is
to develop an optimal treatment regimen for patients
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cases, a suboptimal response may be due to under
stimulation. In patients having shown a poor response to
COH in their first cycle, Lashen et al. [6] investigated
the value of increasing the gonadotropin dose in a sub-
sequent cycle. The authors reported that patients who
received 225 IU or more of gonadotropin daily in cycle 1
showed a similar poor response in their second cycle,
despite the higher starting stimulation dose. Similarly,
three studies [5, 30, 31] showed that increasing the hMG
dose up to 450 IU per day in a second cycle neither in-
creased the number of oocytes retrieved not improved
the treatment cycle outcome, relative to a previous cycle
with a lower hMG starting dose. In our study, although
the initial dose of gonadotrophins was the same with the
three protocols (375 IU/day), the numbers of embryos
obtained for transfer were significantly higher with the
P2 and P3 protocols compared to the first protocol (P1).
Our data support those reported in the literature and
showing that, so far, no specific treatment improves the
outcome in poor responders treated with IVF. Despite
the consensus of Bologna, today there is no one clear
definition of poor responder. In 2003 Toner et al. [32]
reported that female age impacts oocyte quality and that
both AMH and AFC profile affect the number of re-
trieved. To mitigate the negative effect of age, prophylac-
tic oocyte cryopreservation can be proposed after
ovarian stimulation for future use. This perspective is
supported by advances made on vitrification [33]. How-
ever to reach pregnancy it will need between 12 to 15
oocytes [34] and even 22 to 50 depending on the
woman’s age [35]. Today in France this perspective is
not allowed but in the meantime we can offer mild
stimulation to collect lower number of oocytes with bet-
ter quality and giving acceptable number of embryo for
vitrification [36]. This perspective is in line with the
Baart et al. study [37] who found that that lower doses
of gonadotropins are associated with embryos with lower
aneuploidy rates and the Otsuki et al. [38] analysis which
showed that high oestradiol levels can produce oocyte
with vacuolated cytoplasm and reduce the chances of
pregnancy. For poor responders, multiple mild stimula-
tions followed by vitrification can increase the number
of suitable embryo for transfer after thawing and im-
prove clinical pregnancy. Our study showed that the im-
provement of pregnancy rate between protocol P1 and
P2 or P3 is related to the number of suitable good em-
bryos for transfer. In addition sequential transfer after
vitrification on substituted or lightly stimulated cycles
could improve implantation via better endometrial re-
ceptivity and ongoing pregnancy rate [39–41].
Finally, it seems that agonist and antagonist protocols
involving high doses of gonadotropins are not beneficial
in the management of poor responders and that newapproaches need to be developed and proposed for these
unfortunate patients consulting ART centers.
Conclusion
In the present randomized study, we have found that the
implantation and ongoing pregnancy rates per embryo
transferred were not significantly different with the
contraceptive pill + flare-up GnRH-a protocol compared
to the multidose GnRH antagonist protocol. For these
protocols, the prognostic factors for pregnancy were a ma-
ternal age <36, no tobacco consumption, a total FSH/hMG
dose <5,000 IU and an endometrial thickness >10 mm. In
the future we need to tailor our approach in the manage-
ment of poor responders according to the woman’s age
and life style. This can be achieved through a customised
policy involving a mild stimulation strategy [42, 43], se-
quential IVF cycles, oocytes-embryos freeze all policy as
well as blastocyst transfer after screening to improve the
clinical outcome in those unfortunate patients.
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